Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 déc. 2024 16h30 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
26 nov. 2024 16h30 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the Piper Sandler
36th Annual Healthcare Conference
Aclaris Therapeutics Announces $80 Million Private Placement
18 nov. 2024 08h10 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces $80 Million Private Placement
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
18 nov. 2024 08h10 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
06 nov. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
17 sept. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
10 sept. 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
07 août 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
16 juil. 2024 16h01 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
06 juin 2024 07h00 HE
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference